Nektar Therapeutics
Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical
Nektar Therapeutics; Rezpegaldesleukin; Rezpeg; Phase IIb trial; eczema; atopic dermatitis; clinical trial; EASI score; Dupixent; analyst skepticism; Lilly partnership
Nektar Therapeutics Sells Alabama Manufacturing Facility and Reagent Business for $90 Million
Nektar Therapeutics, manufacturing site, reagent arm, divestment, Ampersand, $90 million